🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 85 of 116

  1. A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients with Relapsed or Refractory Lymphoma

    Hutchmed Europe B.V.

    Lymphoma

    phase 1 other active

    1 trial

  2. A Phase I, Open-label, Multi-center, First-in-human Trial to Investigate E303, in Participants with Advanced Refractory Solid Tumors

    Samsung Bioepis NL B.V.

    advanced refractory solid tumors

    phase 1 other active

    1 trial

  3. A Phase IB Study to determine efficacy and safety of Durvalumab and/or novel anti-cancer agents, with or without chemotherapy, in patients with previously untreated NSCLC

    AstraZeneca AB

    Metastatic Non-Small Cell Lung Cancer (NSCLC)

    phase 1 other active

    1 trial

  4. A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

    AbbVie Deutschland GmbH & Co. KG

    Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia

    phase 1 other active

    1 trial

  5. A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients with Metastatic Colorectal Cancer (INTRINSIC)

    Hoffmann-La Roche

    Metastatic Colorectal Cancer

    phase 1 other active

    1 trial

  6. A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

    Hoffmann-La Roche

    Diffuse large B-cell lymphoma (DLBCL), Grade 3B follicular lymphoma, High grade B-cell lymphoma (HGBL), Epstein-Barr virus−positive DLBCL

    phase 1 other active

    1 trial

  7. A Study in Healthy Adult Male Participants to Evaluate the Metabolism of [14C]PF-06821497

    Pfizer Australia Pty Ltd

    small cell lung cancer (SCLC), castration resistant prostate cancer (CRPC), follicular lymphoma (FL)

    phase 1 other active

    1 trial

  8. A Study of GEN1106 in Participants with Solid Tumors

    Genmab A/S

    Metastatic or advanced malignant solid tumors

    phase 1 other active

    1 trial

  9. A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants with Solid Cancers Treated with Cemiplimab

    Lacuna Pharma Pty Ltd

    Advanced Solid Tumor

    phase 1 other active

    1 trial

  10. A Study of JNJ-90301900 in Combination with Concurrent Chemoradiation Therapy in LA HNSCC

    Janssen-Cilag International N.V.

    Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

    phase 1 other active

    1 trial

  11. A Study of LY3200882 in Participants With Solid Tumors.

    Eli Lilly Co.

    Metastatic cancer, Solid Tumor

    phase 1 other active

    1 trial

  12. A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

    Eli Lilly Co.

    Metastatic Solid Tumor Advanced Solid Tumor Non-small Cell Lung Cancer SMARCA4-Deficient Tumor

    phase 1 other active

    1 trial

  13. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

    Eli Lilly Co.

    Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

    phase 1 other active

    1 trial

  14. A Study of LY4175408 in Participants With Advanced or Metastatic Solid Tumors.

    Eli Lilly Co.

    Cancer

    phase 1 other active

    1 trial

  15. A Study of LY4257496 in Participants With Cancer (OMNIRAY)

    Eli Lilly Co.

    Breast Neoplasms Colorectal Neoplasms Prostate Neoplasm Endometrial Neoplasms Neoplasm Metastasis

    phase 1 other active

    1 trial

  16. A Study of PF-08046031 in Adults With Advanced Melanoma and Other Solid Tumors

    Pfizer Australia Pty Ltd

    Melanoma (or) malignant melanoma Non-small cell lung cancer Head and neck squamous cell carcinoma Esophageal cancer

    phase 1 other active

    1 trial

  17. A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Compared to Oral Lenvatinib Capsules in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

    AbbVie Deutschland GmbH & Co. KG

    Squamous-Cell Non-Small Cell Lung Cancer, Hepatocellular Cancer

    phase 1 other active

    1 trial

  18. A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

    AbbVie Deutschland GmbH & Co. KG

    Relapsed/Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  19. A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

    AbbVie Deutschland GmbH & Co. KG

    Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer

    phase 1 other active

    1 trial

  20. A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

    AbbVie Deutschland GmbH & Co. KG

    Follicular lymphoma (FL), Chronic lymphocytic leukemia (CLL), Diffuse large b-cell lymphoma (DLBCL), B-cell malignancies

    phase 1 other active

    1 trial

  21. A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

    Alnylam Netherlands B.V.

    Advanced or Metastatic Hepatocellular Carcinoma

    phase 1 other active

    1 trial

  22. A Study to Evaluate MEDI5752 in Subjects with Advanced Solid Tumors

    AstraZeneca AB

    Advanced solid tumours

    phase 1 other active

    1 trial

  23. A Study to Evaluate Safety and Anti-Tumor Activity of RO7284755 Alone or in Combination with Atezolizumab in Participants with Advanced and/or Metastatic Solid Tumors

    Hoffmann-La Roche

    Solid Tumors

    phase 1 other active

    1 trial

  24. A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors

    Alphapharm Pty Ltd

    Arm A: Diagnosed with uterine serous carcinoma (USC) Arm B: Diagnosed with recurrent or progressive, high-grade epithelial ovarian cancer (EOC) with cyclin E1-driven selection Arm C: Diagnosed with solid tumor with biomarker-driven selection

    phase 1 other active

    1 trial

  25. A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Clinical Activity of RO7276389 Alone and in Combination with Cobimetinib in Participants with BRAF-V600 Mutation-Positive Advanced Solid Tumor or BRAF-V600 Mutation-Positive Melanoma with Central Nervous System Metastases

    Hoffmann-La Roche

    BRAF-V600 Mutation-Positive Advanced Solid Tumor or BRAF-V600 Mutation-Positive Melanoma with or without Central Nervous System Metastases

    phase 1 other active

    1 trial

  26. A Study to Evaluate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Xdivane versus Opdivo® in Patients with Resected Melanoma

    Lacuna Pharma Pty Ltd

    Melanoma

    phase 1 other active

    1 trial

  27. A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Non-Small Cell Lung Cancer with Activating EGFR or HER2 Mutations (FURTHER)

    ArriVent BioPharma

    Non-Small Cell Lung Cancer (NSCLC) harboring activating EGFR or HER2 kinase domain mutations

    phase 1 other active

    1 trial

  28. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Subcutaneous Glofitamab following Obinutuzumab Pretreatment in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

    Hoffmann-La Roche

    Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

    phase 1 other active

    1 trial

  29. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination with Glofitamab in Participants with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma

    Hoffmann-La Roche

    Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r NHL)

    phase 1 other active

    1 trial

  30. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Inavolisib in Combination with Paclitaxel in Patients with Locally Advanced or Metastatic Solid Tumors

    Hoffmann-La Roche

    Locally Advanced or Metastatic Solid Tumors

    phase 1 other active

    1 trial

  31. A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  32. A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants with Advanced Solid Tumors Previously Treated with Standard of Care Therapy

    AstraZeneca AB

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  33. A Study to Investigate the Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia

    Kura Oncology

    Relapsed and/or refractory Acute Myeloid Leukemia

    phase 1 other active

    1 trial

  34. A Study to Learn About How Different Formulations of the Medicine Called Mevrometostat are Taken up Into the Blood in Healthy Adult Participants

    Pfizer Australia Pty Ltd

    Small cell lung cancer, Castration-resistant prostate cancer, Follicular lymphoma

    phase 1 other active

    1 trial

  35. A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed by the Body in Men With Prostate Cancer

    Astellas Pharma GmbH

    Hot Flush

    phase 1 other active

    1 trial

  36. A Study to Learn How a Tablet Compared with an IV Infusion of the Study Medicine Called Vepdegestrant is Taken up into the Blood in Healthy Adults.

    Pfizer Australia Pty Ltd

    ER+/HER2- breast cancer

    phase 1 other active

    1 trial

  37. A Study to Learn If The Study Medicine Called Fluconazole Changes How the Body Processes The Other Study Medicine PF-07248144

    Pfizer Australia Pty Ltd

    locally advanced or metastatic HR+/HER2- breast cancer

    phase 1 other active

    1 trial

  38. A Study to Learn If the Study Medicine Called Vepdegestrant Changes How the Body Processes the Other Study Medicine Called Midazolam

    Pfizer Australia Pty Ltd

    ER+/HER2 positive breast cancer

    phase 1 other active

    1 trial

  39. A Study to Learn More About an Investigational Medicine called HDP-102 in Patients with Relapsed/Refractory B-cell Blood Cancers.

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory B-cell Malignancies

    phase 1 other active

    1 trial

  40. A Study to Learn how Various Tablets of the Study Medicine Called Vepdegestrant are Taken up into the Blood in Healthy Adults

    Pfizer Australia Pty Ltd

    ER+/HER2- Breast Cancer

    phase 1 other active

    1 trial

  41. A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144

    Pfizer Australia Pty Ltd

    locally advanced or metastatic ER+/HER2- breast cancer

    phase 1 other active

    1 trial

  42. A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

    Boehringer Ingelheim

    non-small cell lung cancer or, melanoma, head and neck squamous cell carcinoma

    phase 1 other active

    1 trial

  43. A Study to Test How Safe, Effective and How Body’s Responds to the Combination of Mosunetuzumab and Pirtobrutinib Together to Treat Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

    Hoffmann-La Roche

    Relapsed or Refractory Chronic Lymphocytic Leukemia (R/R CLL)

    phase 1 other active

    1 trial

  44. A Study to assess the Safety, Tolerability and effect of RO7673396 when used alone as well as with other cancer medications in participants with Advanced Solid Tumors

    Hoffmann-La Roche

    Advanced Solid Tumors Harboring RAS Mutation(S)

    phase 1 other active

    1 trial

  45. A Study to see how safe is RO7567132 as Single Agent and in Combination with Atezolizumab, how the body gets rid of it and how effective it is in people with Advanced and/or Metastatic Solid Tumors

    Hoffmann-La Roche

    Advanced and/or Metastatic Solid Tumors

    phase 1 other active

    1 trial

  46. A Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or Refractory Solid Tumors

    AbbVie Deutschland GmbH & Co. KG

    Patients with relapsed or refractory solid tumors, including: Small cell lung cancer (SCLC); Non-small cell cancer (NSCLC); Breast cancer

    phase 1 other active

    1 trial

  47. A clinical study of MK-0472 in people with solid tumors (MK-0472-001)

    Merck Sharp and Dohme

    Malignant Neoplasm - Solid Tumors

    phase 1 other active

    1 trial

  48. A clinical study to evaluate the efficacy of ceritinib in combination with nivolumab in patients with ALK positive lung cancer

    Novartis Pharmaceuticals

    Non-small cell lung cancer

    phase 1 other active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.